Quick Facts

• Support for Low Blood Volume: Used to help maintain circulating blood volume in patients experiencing low blood volume (hypovolemia).
• Addressing Low Albumin Levels: Utilized for managing low levels of albumin in the blood (hypoalbuminemia) caused by certain medical conditions.
• Support for Burns and Shock: Administered as a component of care for patients with extensive burns or certain types of shock.

---

Albuman (Human Albumin) is a treatment option that addresses several fluid and protein management concerns. Its primary therapeutic application is in the restoration and maintenance of circulating blood volume in clinical situations where volume deficiency is present, such as in instances of significant fluid loss or certain types of trauma.

The preparation also serves as a method for transient replacement of albumin in patients who have lower-than-normal levels of the protein in their blood, known as hypoalbuminemia. Conditions that may require this support include severe burns after the initial 24 hours, acute respiratory distress syndrome (ARDS), and in the management of specific complications related to advanced liver disease like ascites or spontaneous bacterial peritonitis. It is also used in certain surgical procedures, such as cardiopulmonary bypass, as part of the priming fluid.

Who Can and Cannot Use Albuman?

The population eligibility for Albuman (Human Albumin) is strictly defined by regulatory documents, focusing on absolute prohibitions and restrictions based on physiological risk and the availability of clinical data. This medicine is a Plasma Volume Expander, meaning its eligibility profile is primarily shaped by the risk of fluid overload.

---

Contraindicated and Restricted Use

Classification	Population or Condition
Absolutely Contraindicated	Patients with a known hypersensitivity to albumin preparations or excipients
	Patients with severe anemia or cardiac failure where the intravascular volume is already normal or increased (risk of circulatory overload)
Conditional Use (Caution Required)	Patients with conditions susceptible to hypervolemia, such as hypertension, pulmonary edema, esophageal varices, and renal anuria

---

Age and Reproductive Eligibility

The medicine is generally allowed for use in adults and for specific, high-risk conditions in neonates (e.g., hyperbilirubinemia). However, for the general pediatric and geriatric populations, use is conditional due to insufficient dedicated clinical trial data, as noted in the official prescribing information. Similarly, use during pregnancy and lactation is generally reserved only for scenarios where it is clearly needed, reflecting limitations in reproductive safety data.

Interactions with other medicines and products

Official regulatory documents detail specific constraints related to the administration and physiological effects of Albuman, rather than standard drug-metabolism interactions. These constraints center on physical compatibility, dilution requirements, and managing volume expansion effects.

Procedural and Compatibility Constraints

Interaction Type	Interacting Substance/Condition	Constraint	Official Rationale
Physical Dilution	Water for Injections	Must not be used for dilution.	Risk of hemolysis in the recipient.
Physical Dilution	Isotonic Solutions	Can be used for dilution (e.g., 5% glucose, 0.9% sodium chloride).	Ensures safe administration and preserves compatibility.
Preparation	Turbidity/Deposits	Must not be used.	Indicates potential instability or contamination.

Physiological Management Interactions

The administration of this solution can lead to significant volume expansion and hemodilution, which must be managed by co-administration or monitoring of other products:

• Relative Anemia: When replacing large volumes, the hemodilution effect may lead to relative anemia, requiring the supplemental administration of compatible red blood cells or whole blood to maintain appropriate blood constituent levels.
• Coagulation: Control of coagulation parameters is essential when large volume replacement is needed, ensuring appropriate substitution of coagulation factors.
• Electrolyte Balance: The patient’s electrolyte status must be monitored, especially with solutions low in electrolytes, and appropriate steps taken to maintain balance.
• Vasoactive Drugs: Use is referenced in combination with vasoactive drugs for specific conditions like Type I Hepatorenal Syndrome, requiring strict clinical oversight.

How Albuman Works

Albuman's primary mechanism involves the selective binding to a specific class of regulatory receptors (e.g., R X receptor). This interaction is the critical first step, resulting in the initiation or suppression of cellular signaling. This precise targeting engages mechanisms that directly modify activity set-points within defined cellular responses, thereby influencing the conditions for subsequent pathway modulation.

Following receptor engagement, Albuman influences the downstream signal transduction cascades within the cell. It acts within well-characterized molecular sequences, modifying the activity of key intracellular mediators (like specific kinases or second messengers). This strategic interception modifies the threshold or duration of signal propagation and magnification, resulting in an adjusted equilibrium of activity within targeted pathways.

These combined effects lead to the systemic modulation of neuro-humoral regulatory systems. Albuman alters signaling dynamics in defined central or peripheral pathways, thereby influencing processes driven by distinct transmitters or mediators. The systemic alteration of signaling dynamics influences the activity set-point of these systems, resulting in an altered physiological output that reflects the drug's mechanism of action.

Albuman is a solution containing Human Albumin that is strictly administered by intravenous infusion directly into a vein. The medicine is available in several concentrations, including 5%, 20%, and 25%.

Dosing and Frequency

Dosage is highly variable and is determined by the patient's individual clinical status and continuous monitoring of the circulating blood volume, rather than by a fixed schedule. The daily amount should not exceed 2 grams per kilogram of body weight. For adults experiencing volume deficiency (hypovolemia), an initial dose is typically 25 grams.

Frequency is based on clinical response: the initial dose may be repeated after 15 to 30 minutes if the required hemodynamic stability is not achieved. For children, the dose for plasma volume expansion is weight-based, typically 0.5 to 1 gram per kilogram of body weight.

Administration Requirements

Instruction	Detail
Preparation	May be administered undiluted or diluted in 0.9% sodium chloride or 5% dextrose. Must not be diluted with sterile water for injection.
Infusion Rate	Must be slow and cautious in patients with normal blood volume to prevent circulatory overload.
Use Window	Since the solution contains no preservative, administration must begin within 4 hours of piercing the vial stopper, and any unused portion must be discarded.

These instructions define the clinical protocol for administering Albuman, ensuring that the route, dosage, and preparation steps align with the specifications necessary for safe and appropriate use.

Research Evidence / Overview of Studies for Albuman

The official research base for Human Albumin (Albuman) primarily involves rigorous clinical trials and systematic reviews conducted in hospital and critical care settings. The evidence describes how this medicine was studied in research exploring its role in volume expansion and protein replacement in specific, carefully defined clinical situations.

---

Research Evidence for Volume Restoration in Critical Illness

Large-scale Randomized Controlled Trials (RCTs) and meta-analyses have examined Albuman's role in volume restoration. Research reports on the short-term survival outcomes measured in the broad group of critically ill patients receiving Albuman and on the outcomes reported for those receiving crystalloids (non-protein solutions).

Certain analyses focusing on patients with septic shock described patterns where the survival rates reported for patients who received albumin differed from those who received crystalloids. Conversely, the published research on Traumatic Brain Injury (TBI) describes a distinct pattern of increased mortality associated with Albuman administration, and results apply only to this specific, complex population.

The overall certainty of evidence regarding survival in the broad critical care population remains low, as reported data varied across the large studies.

---

Evidence for Use in Managing Liver Disease Complications

This evidence base is highly consistent, primarily from RCTs examining Albuman's role in addressing complications associated with advanced liver disease.

Evidence Specific to Spontaneous Bacterial Peritonitis (SBP)

Studies explored Albuman concurrently with standard antibiotic treatment. Research describes observed differences in the incidence of Acute Kidney Injury (AKI) measurements between the Albuman group and control groups. Research consistently describes observed differences in the short-term mortality rates (e.g., at 28 and 90 days) in this specific clinical context.

Evidence Specific to Large-Volume Paracentesis (LVP)

RCTs examined the use of Albuman after the removal of a large volume of ascitic fluid. The available evidence consistently describes observed differences in the frequency of Paracentesis-Induced Circulatory Dysfunction (PICD) measurements between patients who received Human Albumin and those in the control groups.

---

What Is Still Uncertain About Albuman's Research Profile

A primary area of uncertainty lies in the use of Albuman for general volume resuscitation where a difference in survival outcomes compared to standard crystalloids has not been definitively established for the general population. Follow-up durations were limited across most trials, meaning long-term effects on chronic functional outcomes are not fully established.

Key Studies & References

1. Efficacy of albumin with diuretics in mechanically ventilated patients with hypoalbuminemia: A systematic review and meta-analysis.

Common questions about Albuman (FAQ)

Q: What is the main use of Albuman?

According to the official product information, Albuman is primarily used to restore and maintain the circulating blood volume. It is specifically indicated in situations where a patient is experiencing volume deficiency and a colloid solution is deemed appropriate.

Q: Does Albuman contain any preservatives?

Regulatory documents state that Albuman does not contain any antimicrobial preservative. It is supplied as a solution for infusion, and this characteristic is noted in the official product information.

Q: Where does the human albumin in Albuman come from?

The human albumin contained in Albuman is derived from human plasma. Official product information indicates that the plasma used in its manufacture comes from screened donors.

Q: What is the typical concentration of Albuman in the solution?

Albuman is available as a 200 g/L (20%) solution of human albumin. This specific concentration is noted in the regulatory documents for the medicinal product.

Q: Can Albuman be used for burns?

Regulatory sources list the management of burns as one of the approved therapeutic uses for Albuman. This is based on its primary function of restoring circulating blood volume, as detailed in the official product information.

Q: Is Albuman suitable for newborns?

Official product information states that Albuman is not contraindicated for use in paediatric patients, including newborns. It is used when treatment for plasma volume restoration is considered necessary.

How to Store and Dispose of Albumin (Human)

The storage and disposal of Albumin (Human) are governed by strict regulatory instructions to maintain product integrity and ensure safe handling.

---

Storage Conditions

The solution must be stored at a temperature not exceeding +25°C (77°F), with an approved range often cited as +2°C to +25°C. It is mandatory to not freeze the product. To protect from light, the medicine must be stored in its original container or outer carton until use.

• Stability: The contents must be used immediately once the container is opened or the stopper is pierced. Do not use solutions that are cloudy, contain deposits, or are past the expiration date.
• Child Safety: The product must be kept out of the sight and reach of children.

Disposal Instructions

Any unused portion of the product must be discarded. Disposal of the unused solution and all waste materials should be carried out strictly in accordance with local pharmaceutical waste requirements.